Statin Recommendations among US Adults with the 2026 Dyslipidemia Guidelines
Fuente:
arXiv
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Preprint |
| Published: |
2026
|
| Subjects: | |
| Online Access: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1866910209734082560 |
|---|---|
| author | Diao, James A. Buckley, Thomas A. Zhou, Andrew Z. Dash, Smaraki Wadhera, Rishi K. Manrai, Arjun K. |
| author_facet | Diao, James A. Buckley, Thomas A. Zhou, Andrew Z. Dash, Smaraki Wadhera, Rishi K. Manrai, Arjun K. |
| contents | Importance: The 2026 multisociety dyslipidemia guideline recommended the PREVENT equations in place of the PCE equations, introduced 30-year risk assessment as a new treatment pathway, and lowered risk-based treatment thresholds. The net population impact of these concurrent changes on statin recommendations is unknown.
Objective: To estimate changes in statin recommendations under 2026 PREVENT-based dyslipidemia guidelines compared with 2018 PCE-based guidelines.
Design and Participants: Cross-sectional analysis of pooled data from NHANES, spanning 2011-2023 and comprising 24,199 participants aged 30-79 years.
Main Outcomes and Measures: Number and proportion of US adults receiving or recommended for statin therapy.
Results: At the class 1 threshold, the number of US adults receiving or recommended for statin therapy decreased by an estimated 3.0 million (95% CI, 2.3 million to 3.6 million), with larger reductions among Black adults (-4.2 percentage points [pp]), men (-4.0pp), and adults aged 50-69 years (-5.6pp). At the class 2 threshold--which additionally recommends statins for adults aged 30-59 years based on 30-year risk--the number of adults recommended increased by an estimated 20.8 million (95% CI, 19.6 million to 22.0 million), or +11.6pp. The increase was largest among adults aged 50-59 years (+19.7pp) and 40-49 years (+14.8pp).
Conclusions: The net population impact of the 2026 dyslipidemia guidelines depends critically on which recommendation class is applied. At the class 1 threshold, statin recommendations decreased modestly; at the class 2 threshold, inclusion of 30-year risk assessment substantially expanded recommendations, particularly among younger adults. These divergent effects underscore the importance of the 30-year risk criterion as a major driver of new eligibility and the need for outcomes and equity monitoring during guideline implementation. |
| format | Preprint |
| id |
arxiv_https___arxiv_org_abs_2605_10979 |
| institution | arXiv |
| publishDate | 2026 |
| record_format | arxiv |
| spellingShingle | Statin Recommendations among US Adults with the 2026 Dyslipidemia Guidelines Diao, James A. Buckley, Thomas A. Zhou, Andrew Z. Dash, Smaraki Wadhera, Rishi K. Manrai, Arjun K. Other Quantitative Biology Importance: The 2026 multisociety dyslipidemia guideline recommended the PREVENT equations in place of the PCE equations, introduced 30-year risk assessment as a new treatment pathway, and lowered risk-based treatment thresholds. The net population impact of these concurrent changes on statin recommendations is unknown. Objective: To estimate changes in statin recommendations under 2026 PREVENT-based dyslipidemia guidelines compared with 2018 PCE-based guidelines. Design and Participants: Cross-sectional analysis of pooled data from NHANES, spanning 2011-2023 and comprising 24,199 participants aged 30-79 years. Main Outcomes and Measures: Number and proportion of US adults receiving or recommended for statin therapy. Results: At the class 1 threshold, the number of US adults receiving or recommended for statin therapy decreased by an estimated 3.0 million (95% CI, 2.3 million to 3.6 million), with larger reductions among Black adults (-4.2 percentage points [pp]), men (-4.0pp), and adults aged 50-69 years (-5.6pp). At the class 2 threshold--which additionally recommends statins for adults aged 30-59 years based on 30-year risk--the number of adults recommended increased by an estimated 20.8 million (95% CI, 19.6 million to 22.0 million), or +11.6pp. The increase was largest among adults aged 50-59 years (+19.7pp) and 40-49 years (+14.8pp). Conclusions: The net population impact of the 2026 dyslipidemia guidelines depends critically on which recommendation class is applied. At the class 1 threshold, statin recommendations decreased modestly; at the class 2 threshold, inclusion of 30-year risk assessment substantially expanded recommendations, particularly among younger adults. These divergent effects underscore the importance of the 30-year risk criterion as a major driver of new eligibility and the need for outcomes and equity monitoring during guideline implementation. |
| title | Statin Recommendations among US Adults with the 2026 Dyslipidemia Guidelines |
| topic | Other Quantitative Biology |
| url | https://arxiv.org/abs/2605.10979 |